Save Product
Product Details
Synonyms
B7-H4, VTCN1, B7S1, B7h.5
Source
Human B7-H4 Protein, Fc Tag (B74-H5256) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Ala 258 (Accession # Q7Z7D3-1).
Predicted N-terminus: Phe 29
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.8 kDa. The protein migrates as 66-85 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human B7-H4 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human B7-H4 Protein, Fc Tag (Cat. No. B74-H5256) at 0.5 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
V-set domain-containing T-cell activation inhibitor 1
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
11 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
